Kota Toshimoto

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3

Takashi Yoshikado, Kota Toshimoto, Kazuya Maeda et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 75 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

Ryuta Asaumi, Kota Toshimoto, Yoshifusa Tobe et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 57 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins

Takashi Yoshikado, Kota Toshimoto, Tomohisa Nakada et al. · Drug Metabolism and Disposition · 2017 · 52 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography

Kenichi Kaneko, Masaaki Tanaka, Akira Ishii et al. · Drug Metabolism and Disposition · 2018 · 50 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine

Kotaro Nishiyama, Kota Toshimoto, Wooin Lee et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 39 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17